A long-term treatment of patients with acute coronary syndrome is necessary in order to prevent new cardic events to come into being. It presuposes life style change, modification of risk factors as well a medications for second prevention.Stevan Ilić...
Despite a great deal of interest in secondary prevention following an acute coronary syndrome (ACS), with particular attention on antiplatelet and antithrombotic therapies, the standard of care has remained essentially unchanged for the better part of a decade. While a significant number of subsequent...
摘要: Ticagrelor is an alternative to clopidogrel for secondary prevention of cardiovascular death in patients with acute coronary syndrome. In an international study it was found to be more effective, but patients in the United States did not experience superior outcomes....
patients with chronic or acute coronary syndrome, respectively) and chronic (i.e., long-term secondary prevention; after completion of six or 12 months of DAPT, in patients with chronic or acute coronary syndrome, respectively) settings... S Husted 被引量: 0发表: 2018年 Dual Antiplatelet or...
Acute coronary syndromes (ACS) refer to a group of clinical syndromes that result in a reduction in blood flow to myocardium. ACS is a highly prevalent and an important cause for morbidity and mortality worldwide. Potent antithrombotic and anticoagulant therapy is the mainstay of treatment with ...
The problem of acute coronary syndrome (ACS) associated with the frailty in the elderly has received widespread attention,and there are many correlations in the pathogenesis between them.With the increase of age,the incidence of frailty after ACS is higher and higher,which seriously affects the pr...
In-stent restenosis (ISR) has been shown to be correlated with inflammation. This study aimed to examine the relationship between systemic immune-inflammation index (SII, an innovative inflammatory biomarker) and ISR in acute coronary syndrome (ACS) pati
摘要: BACKGROUND: The persistence of depressive symptoms after hospitalization is a strong risk factor for mortality after acute coronary syndromes (ACS). Poor adherence to secondary prevention behaviors may be a mediator of the relationship between depression and increased mortality....
Acute coronary syndrome (ACS) patients treated with inpatient coronary artery bypass graft (CABG) surgery are at significant risk for future Major Adverse Cardiovascular events (MACE). The use of evidence-based medications (aspirin, statins, beta-blockers and angiotensin converting enzyme (ACE) inhibi...
A. et al. Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404–1413 (2012). Article CAS PubMed Google Scholar Whellan, D. J. et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis ...